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by colostomy, 0.9% by image guided drainage, 0.7% by washout, 0.62% by abscess, 
0.42% by re-anastomsis, and 0.01% by stent. Patients with leaks tended to be slightly 
younger and male, had higher Charlson Co-morbidity Index, and more likely admit-
ted through emergency vs. elective surgery (p< 0.05). ConClusions: Our study 
indicated an incidence rate of 6.38% for post-operative anastomotic leaks among 
patients undergoing colorectal surgeries in UK, compared to 6.18% leak rate seen 
in the US study. The results highlight the importance of future study in evaluating 
the impact of anastomotic leaks on patient’s clinical and economic outcomes in UK.
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ResouRce use and dIsease PRoGRessIon amonG HcV-PosItIVe PatIents
Degli Esposti L.1, Sangiorgi D.1, Rizzardini G.2, Perno C.F.3, Buda S.1
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objeCtives: Hepatitis C is an infectious disease affecting the liver; chronic infection 
can lead to cirrhosis. The actual standard of care in Italy is Peginterferon+ribavirin. 
Our aim was to describe treatment patterns, disease progression and resource use 
in HCV. Methods: An observational retrospective cohort analysis based on 4 Local 
Health Units administrative and laboratory databases was conducted. HCV-positive 
patients between January 1, 2009- December 31, 2010 were included and followed-up 
for one year. To explore which covariates were associated to disease progression 
(cirrhosis, hepatocellular carcinoma -HCC-, death for any cause), Cox proportional 
hazards models were performed. Results: A total of 9514 patients were analyzed, 
55.6% male, age 58.1±16.1; 5.8% had HIV, 3.0% HBV, 1.6% HCV+HBV+HIV, 26.1% cir-
rhosis, 4.3% HCC. Genotypes frequencies were 1a (17%), 1b (34%), 2 (24%), 3 (19%), 4 
(5%). Antiviral treatment was not administered to the majority of patients (79%); the 
main factors affecting this decision were: age > 65 years (44%), females (46% VS 40% 
of treated), cirrhosis (30%), normal liver enzymes (28%), ongoing substance/alcohol 
abuse (7%), HCC (5%). Disease progression in the observed timeframe was less fre-
quent among treated patients (incidence rate per 100 patients/year: cirrhosis 2.1±0.7 
VS 13.0±1.0, HCC 0.5±0.3 VS 3.6±0.5, death for any cause 0.5±0.3 VS 6.4±0.7); at multi-
variable Cox regression models, hazard ratios were, respectively, 0.30 (0.21-0.43), 0.41 
(0.19-0.92) and 0.24 (0.12-0.48) (all p< 0.05). For genotype1 subgroup, results were not 
statistically different between Peginterferon+ribavirin treated and untreated (cir-
rhosis: HR= 0.82 (0.32-2.11), p= 0.682). The annual expenditure for HCV management 
(drugs, hospitalizations, outpatient services) was € 4,700 per patient. ConClusions: 
Actual standard of care was not widely used, especially for sensitive subgroups such 
as women and the elderly; in this context, there is an urgent need for treatment, 
but current therapies do not appear to be adequate for all patients, especially those 
with genotype1, which represents 60% of the Italian HCV population.
GastRoIntestInal dIsoRdeRs – cost studies
PGI11
PeRItonItIs FluId tReatment In RussIan FedeRatIon: eValuatIon oF 
economIcal BuRden In Real clInIcal PRactIce
Yagudina R., Kulikov A., Murashko M.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: Peritonitis is an inflammation of the parietal and visceral peritoneum 
which is accompanied by severe general condition of the body. Peritonitis as a com-
plication of acute inflammatory diseases of the abdominal cavity is found in 15-20% 
of clinical observation and about 6% of all surgical procedures on the abdominal 
cavity. The research is conducted in regard to 4 technologies of fluid treatment, 
including: Reamberin, Ringer’s solution, Plasma-Lyte and Sterofundin. Methods: 
Retrospective researches analysis is considered as a source of data on real effective-
ness. The decree of the RF Ministry of Health No 669 of October 15, 2007 is considered 
as a source of data on commonly used drugs and medical services. The price-list of 
the Clinical Center of the First MSMU charges for medical services is incorporated 
as the source of data on the price of medical services. Results: The calculation 
is made for the hypothetical group of 100 patients with the peritonitis disease. 
During the cost of illness analysis of peritonitis the direct costs are estimated. They 
include: medical services and pharmacotherapy in the period of the residence in the 
in-patient department(euro per patient: 9 241 for Reamberin, 10 554,8 for Ringer’s 
solution, 9 755,7 for Plasma-Lyte and 9 756,4 for Sterofundin). The cost-effectiveness 
analysis(CEA) results are the following: 10 241 euro for Reamberin, 12 639 euro for 
Ringer’s solution, 12 302 for Plasma-Lyte and 11 683 euro for Sterofundin. The budget 
impact analysis(BIA) show that the 100% switching patients from Ringer’s solution, 
Plasma-Lyte and Sterofundin to Reamberin saves respectively: 131 377 euro, 51 465 
euro and 51 538 euro. ConClusions: Cost of illness analysis, CEA and BIA of peri-
tonitis indicate that the scheme of therapy including Reamberin is the dominant 
one. Total costs are 9 241 euro per patient, CER is 10 241 euro per saved live.
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objeCtives: To present the critical points concerning organizational and economic 
issues of the introduction of boceprevir in the treatment of patients with genotype 1 
chronic hepatitis C in Italy. Methods: A budget impact analysis was conducted adapt-
ing the NICE (UK) scheme for this drug, using the Italian epidemiological context and the 
perspective of the National Health Service. The cost-utility analysis (CUA) was carried out 
using a Markov model comparing the triple therapy (TT) with peginterferon alfa, ribavirin 
and boceprevir to the double therapy (DT) with peginterferon alfa and ribavirin. Available 
Italian published scientific literature provided data source. The main outcome of the 
CUA was the incremental cost-effectiveness ratio (ICER). The organizational aspects 
PGI7
cHaRacteRIstIcs oF cHIldRen and adolescents usInG PRoton PumP 
InHIBItoRs oR HIstamIne-2-RecePtoR antaGonIsts: analysIs oF tHIn 
and PHaRmo dataBases
Ruigómez A.1, Houweling L.M.A.2, García-Rodríguez L.A.1, Penning-van Beest F.J.A.2,  
Herings R.M.C.2
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objeCtives: To describe demographics and co-morbidities of children starting 
PPI or H2RA use. Methods: Data were obtained from The Health Improvement 
Network (THIN, a UK primary care database) and the Dutch PHARMO Database 
Network (including outpatient pharmacy and hospital databases). Children (< 19 
years) starting a PPI or H2RA between 2009–2012 (THIN) and 2008–2010 (PHARMO) 
were selected. Demographics, medical history, co-morbidities and co-medication 
were assessed. Results: The study included 15782 PPI starters (THIN, n= 5957; 
PHARMO, n= 9825) and 8980 H2RA starters (THIN, n= 5696; PHARMO, n= 3284). The 
proportion of males was similar between PPI and H2RA starters in each database 
(THIN, 41% vs 48%; PHARMO, 44% vs 48%). H2RA starters more often were < 12 years 
of age (THIN, 73% vs 26%; PHARMO, 58% vs 36%) and PPI starters more often had 
received other prior acid-suppressing treatment (THIN, 9% vs 2%; PHARMO, 10% vs 
7%). In THIN, a history of infectious or respiratory disease was more common in PPI 
starters: infectious disease, 89% vs 65% (odds ratio (OR) 1.20; 95% confidence interval 
(CI) 1.05–1.37); respiratory disease, 77% vs 49% (OR 1.20; 95%CI 1.08–1.34). In PHARMO, 
PPI starters were also more likely to suffer from asthma/chronic obstructive pulmo-
nary disease (8% vs 6% (OR 1.35; 95%CI 1.14–1.60)) and more often used antibiotics 
(20% vs 13% (OR 1.53; 95%CI 1.37–1.72)) and non-steroidal anti-inflammatory drugs 
(25% vs 5% (OR 4.48; 95%CI 3.80–5.29)). PPI starters in PHARMO were also more likely 
to have a history of diabetes or epilepsy (diabetes, 1% vs < 0.5% (OR 5.00; 95%CI 
2.33–10.73); epilepsy, 2% vs 1% (OR 1.69; 95%CI 1.16–2.45)). ConClusions: Results 
from both databases indicated that H2RA starters were younger than PPI starters. PPI 
starters were more likely to have received other prior acid-suppressing treatment 
and had more co-morbidities than H2RA starters.
PGI8
HePatocellulaR caRcInoma: an ePIdemIoloGIcal and manaGement 
suRVey-Based analysIs In Italy
Cicchetti A.1, Gasbarrini A.2, Ruggeri M.1, Sacchini D.2
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objeCtives: To verify how Hepatocellular Carcinoma (HCC) management is carried 
out in Italy and to point out the organizational key variables useful for an economic 
assessment, considering that Italy is among the European States with the highest 
incidence of HCC according to recent published data and that HCC is the final and 
highest cost health state along the natural history of liver diseases. Methods: A 
questionnaire was set up jointly by clinicians (hepatologists and infectivologists), 
pharmacoeconomists and HTA experts, and submitted to 9 centers in order to col-
lect epidemiology and management data. The survey consisted of a series of ques-
tions regarding HCC patients: gender and age, HCC etiology, BCLC (Barcelona Clinic 
Liver Cancer) staging at diagnosis, current treatments, hospitalization regimens, 
number and description of diagnostic/outpatient procedures, other relevant concur-
rent pathologies. The survey was administered to patients in four Italian centers 
of excellence for liver diseases with well-established experience in treating HCC 
patients. Results: A total of 596 questionnaires were collected, the majority of 
which regarding male patients (79%), with a mean age of 67. Etiology proved to be 
mainly HCV-related (56%) and most patients underwent full hospitalization (81%) 
with a mean duration of 16.5 days, with a wide variability among centers, concern-
ing both diagnostic procedures (CT, MRI, ecography…) and treatments (surgery, liver 
transplantation, drugs…). ConClusions: The collected data show a major hetero-
geneity, linked to the different etiology and epidemiology of the disease along the 
peninsula, well characterized by a number of published studies, but prove to be very 
helpful in describing the current situation regarding HCC in Italy. This descriptive 
analysis will be useful to set up a prospective study with the aim to implement an 
economic model able to compare different treatments and diagnostic procedures, 
and including organizational aspects in accordance to a cluster-randomized logic.
PGI9
IncIdence oF anastomotIc leaks aFteR coloRectal suRGeRIes usInG 
HosPItal ePIsode statIstIcs In tHe unIted kInGdom
Riebman J.1, Lim S.1, Gao X.2, Delatore P.1, Wan Y.2
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objeCtives: Reported incidence of gastrointestinal anastomotic leaks after colorec-
tal surgeries varies across regions, mainly due to different definitions of anastomotic 
leaks. A recent study using Premier Perspective administrative database reported 
6.18% incidence of post-operative anastomotic leaks in US. The objective of this 
study is to apply a similar definition of anastomotic leaks from the US study and 
estimate incidence of anastomotic leaks after colorectal surgeries in UK. Methods: 
Hospital Episode Statistics database was used to identify patients receiving colo-
rectal surgeries from January 2007 to December 2011. The index colorectal sur-
geries included colectomy, hemicolectomy, sigmoid colectomy, and low anterior 
resection identified by OPCS-4 codes. The anastomotic leak event was defined by 
re-intervention (OPCS-4 codes) or diagnosis (ICD-10 codes) within 30-day window 
following index colorectal surgeries. The re-intervention included re-operation, re-
anastomosis, stent, colostomy, image guided drainage, abscess, and washout. The 
diagnosis was generalized acute peritonitis. Chi-square and t tests were used to 
compare demographic characteristics between patients who had leaks and those 
who did not. Results: A total of 132,045 patients (mean age: 65 years, 50% male) 
received colorectal surgeries during 2007-2011. Of these, 8,434 (6.38%) had anas-
tomotic leaks within 30 days of the colorectal surgeries. 2.63% leak cases were 
defined by reoperation, 1.82% by diagnosis of generalized acute peritonitis, 1.24% 
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treated. The savings mainly resulted from shorter operating time (13 Minutes) and 
decreased hospital stay (0.7 days). ConClusions: Although the instrument cost 
is higher for the ultrasonic device, the total procedural cost is lower compared 
to electrosurgery. Utilization of the Harmonic® ultrasonic device in laparoscopic 
cholecystectomy can lead to substantial cost savings for US hospitals.
PGI16
moRtalIty and medIcal costs assocIated wItH lIVeR-Related 
dIseases amonG PatIents wItH HePatItIs c VIRus(HcV) InFectIon In 
taIwan
Tang C.H., Huang K.C., Huang S.Y., Wu Y.T., Lin K.D.
Taipei Medical University, Taipei, Taiwan
objeCtives: To examine the mortality and medical costs during the first and the 
2nd year following the onset of the five liver-related diseases, i.e. HCV infection, 
compensated cirrhosis (CC), decompensated cirrhosis (DCC), hepatocellular carci-
noma (HCC), or liver transplantation. Methods: Patients with HCV infection and 
patients who transitioned to the health state of liver-related disease were identi-
fied from the National Health Insurance Research Database (NHIRD) during 2008-
2010 if any outpatient/inpatient service with primary diagnosis code of 070.54 for 
HCV infection or 571.5 for CC occurred, or if patients registered in the Registry of 
Catastrophic Illness with diagnosis code of 571.5 for DCC, 155 for HCC or V42.7 for 
post liver transplantation. Dual infection patients with diagnosis code of 070.30 for 
HBV or 042-044 for HIV were excluded. The date that the outpatient visit/admission 
with the diagnosis code associated with each health state of liver-related disease 
firstly occurred was defined as the index date. Regression-adjusted medical costs 
associated with each health state of liver-related disease within 1st year and 2ndyear 
after the index date were estimated by generalized linear regression model. Excess 
risks of death for patients with DCC, HCC, or liver transplantation were assessed 
by Cox proportional hazard model. Results: First year total medical costs associ-
ated with HCV infection, CC, DCC, HCC and liver transplantation were NT$25,345, 
NT$49,793, NT$187,428, NT$197,835, NT$487,816, respectively. The 2nd year total 
medical costs associated with DCC, HCC and liver transplant were NT$194,016, 
NT$176,167 and NT$270,009, respectively. Patients in the health states of DCC, HCC 
and liver transplantation posed higher risk of death with hazard ratio of 14.5when 
compared with their matched control counterparts. ConClusions: Liver-related 
diseases followed by HCV infection impose substantial economic burdens to the 
National Health Insurance in Taiwan. Effective treatment for HCV infection may 
imply potential savings to the society.
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ResouRce utIlIzatIon and costs FoR PatIents wItH InFlammatoRy 
Bowel dIseases In Italy: a PoPulatIon-Based assessment
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Danese S.2, Cesana G.1
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objeCtives: To describe health care resource utilization in treating patients 
affected by inflammatory bowel diseases (IBD) and to assess the related direct costs 
to the Italian health care system (HS) in its most populated region. Methods: A 
retrospective observational study was conducted using data from DENALI, a data 
warehouse that organizes and integrates the health care administrative databases 
of the national HS in Lombardy (northern Italy) with a probabilistic approach. The 
Italian HS provides universal coverage and records the accesses to health care ser-
vices at regional level. We enrolled adult patients with Ulcerative Colitis (UC) or 
Crohn’s Disease (CD) diagnosed during the period 2003-2009. Patients were classi-
fied in two cohorts in relation to the type of IBD and were followed until December 
31st, 2009 to assess the mean annual consumption of resources (hospitalizations, 
pharmaceutical prescriptions, outpatient services) and the related costs incurred by 
HS. Results: We identified 5,523 patients with UC and 3,321 with CD and the mean 
annual cost per-capita was € 2,386 (95%CI: 2,241-2,516) and € 2,699 (95%CI: 2,538-
2,914) respectively. The breakdown of expense was similar in the cohorts: pharma-
cological treatments accounted for 37% , hospitalizations for 47% and outpatient 
services for 16%. Use of mesalamine was high in patients with UC and CD:94% and 
88% of subjects was respectively prescribed at least one package during follow-up. 
High adherence (≥ 70%) to oral mesalamine was observed in 39% of patients with 
UC and in 24% of CD cohort. Less than 6% of patients used biologics, which were 
used only from 2008. ConClusions: This study confirms that patients with IBD 
represent a considerable economic burden for the Italian HS: prescribed drugs, 
especially mesalamine, account for a substantial proportion of health care costs. 
The results underline the importance of administrative databases and the need 
for further research, since the recent widespread use of biologics for treating IBD.
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utIlIsatIon and costs oF InPatIent and outPatIent seRVIces amonG 
PatIents wItH IRRItaBle Bowel syndRome- a study usInG tHe clInIcal 
PRactIce ReseaRcH datalInk (cPRd)
Murray-Thomas T.1, Dedman D.1, Canavan C.2, West J.2, Card T.2
1Medicines and Healthcare Products Regulatory Agency, London, UK, 2University of Nottingham, 
Nottingham, UK
objeCtives: Irritable bowel syndrome (IBS) is a common functional gastrointestinal 
disorder. We assessed utilisation of secondary care services and associated costs 
among patients with IBS. Methods: IBS was identified by medical diagnosis and/
or prescribing in the UK primary care setting. Patients had ≥ 12 months of medical 
history prior to diagnosis. Absolute resource use and expenditure were assessed 
post IBS and over four years (01/04/2008-31/03/2012) using Hospital Episode Statistic 
data. Inpatient admission, outpatient attendance and length of stay for any cause 
including IBS related conditions were assessed. Inpatient costs for the period were 
estimated using allocated Health Resource Group coded data. Outpatient costs 
considered were: clinical management of patient with HCV chronic infection, access 
modalities, outpatient visit, planned and unplanned visits, hospital admission, role of 
the general practitioner (GP). Results: The budget impact analysis shows that, consid-
ering both naïve and previously treated patients, the treatment with boceprevir has an 
impact on the National Health Service of almost € 66 million for the first year. Compared 
to treatment with DT, the cost-utility analysis shows for the boceprevir-based treatment 
strategy an ICER of € 8.622,00. The management of TT for its intrinsic complexity requires 
monthly outpatients visits, at least at the beginning of treatment, for monitoring the 
compliance to treatment, efficacy and side effects. A critical organizational point is 
potentially the request for boceprevir for each single patient by the medical prescriptor, 
who needs to fill in detailed form from the Italian Agency of Drug (AIFA). ConClusions: 
The impact of the introduction of boceprevir on the budget is high, even if the ICER is 
favourable. Patients’ management is particularly complex and there is the need for an 
alliance between the patients, their relatives, GPs and specialized centers.
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enteRal dIets (ed): a cost-comPaRIson analysIs FoR In-HosPItal 
PRePaRatIons Based on Real woRld oBseRVatIon
Clark O.A.C.1, Paladini L.1, Nishikawa A.M.1, Borges L.1, Arraiz A.2
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objeCtives: ED can be administered based on three different systems – powder 
based (Po), open, liquid (Op), and a completely closed (Cl). There are differences in the 
preparation, installation and delivery and in the diarrhea rates among them. Our aim 
was to measure the total costs for each system, considering the resources needed to 
prepare, delivery administer and discard of each system (hidden costs). Methods: 
We measured the human (nurse, nutritionist, auxiliary personnel) resources involved 
in ED preparations in three hospitals of Brazil. Then, we calculated the costs of the 
process, based on the minimum official wage for each professional category. After, we 
added the costs of the diets and materials needed to the infusion. We used as base 
case a daily need of 1 000Kcal / patient. Additional analyses were performed to include 
the side effects of ED system. Results: There were differences among the human 
resources needed for each system. Hidden costs were 63% of the total for Op, 58% for Po 
and 53% for Cl. Particularly, the nurse time varied from 18 minutes for Po and Op and 5 
min for Cl for each infusion. Considering that and average patient would require daily 
4 infusions of Po or Op, that represents a total of 72min of nurse time to these systems, 
against 5 min to Cl. Total daily costs, were Op US$ 62.05; Po US$ 50.75 and Cl US$48.03. 
If we consider the costs of side effects, such as diarrhea, the costs are: Op US$ 73.42; 
Po US$ 62.15 and Cl 56.35. This increase in the difference amog the costs is due to a 
lower incidence of diarrhea in Cl systems. ConClusions: There are many hidden 
costs on the ED systems. If we consider them Cl systems are less costly than Op and Po.
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cost analysIs oF PRoton PumP InHIBItoRs In tHe tReatment oF ulceR 
duodenum In ukRaIne
Iakovlieva L., Gerasymovà O., Mishchenko O., Kuznetsov I., Kyrychenko O., Tkachova O.
National University of Pharmacy, Kharkiv, Ukraine
objeCtives: Proton pump inhibitors (PPIs) are essential components schemes of 
antyhelicobacter therapy (AT) of peptic ulcer disease. The aim of research - to deter-
mine the costs of the use of PPIs in the traditional triple schemes AT (first and second 
line) of the working age patients with a duodenal ulcer in Ukraine. The objects of 
research - preparations of omeprazole, pantoprazole, rabeprazole, lansoprozol, ezome-
prazol, which are present in Ukraine. Methods: Cost analysis on the use of PPIs in 
the schemes of AT was performed per one patient for 14 days with the daily doses of 
drugs: omeprazole - 40 mg, pantoprazole - 80 mg, rabeprazole - 40 mg, lansoprozol - 60 
mg, ezomeprazol - 40 mg (according to the recommendations of the “Maastricht IV”, 
2010). For determining the costs only the costs of the PPIs were taken into account. 
The prices of drugs were taken from the information system “Drugs” of Company 
“Morion” (December, 2012). The currency ratio of UAH to dollar (USA) on 10.12.12 was 
7.99:1. To determine the range of costs for use of PPIs determined their trade names 
with the minimum and maximum costs for the AT. Results: The range of costs for 
use of PPIs in the traditional triple schemes AT in Ukraine is wide enough, respectively: 
omeprazole - 1.15 - 19.15 $, pantoprazole - 5.11 - 49.28 $, lansoprozol - 5.14 - 10.66 $, 
rabeprazole - 4.27 - 63.40$, ezomeprazol 1.81 - 36.42$. ConClusions: Costs only for 
the use of PPIs in the schemes of AT of duodenal ulcer can be quite high in Ukraine. 
In this regard, the choice of PPIs for inclusion in the schemes of AT is advisable to use 
the results of pharmacoeconomic studies that will optimize the costs of the payer.
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economIc analysIs oF use oF HaRmonIc deVIces In InPatIent 
laPaRoscoPIc cHolecystectomy In tHe unIted states
Cheng H.1, Hinoul P.1, Clymer J.1, Vaughn B.2
1Johnson & Johnson(Ethicon Endo Surgery, Inc), Cincinnati, OH, USA, 2Johnson and 
Johnson(Ethicon, Inc), Somerville, NJ, USA
objeCtives: Harmonic® ultrasonic energy devices have been developed as a safer 
and more efficient alternative to traditional electrosurgery (monopolar and bipolar) 
in laparoscopic cholecystectomy. However, the economic impact on hospital cost 
has not yet been assessed in the United States. The aim of the study is to evaluate 
the total cost of laparoscopic cholecystectomy performed with an ultrasonic device 
versus electrosurgery from a hospital perspective. Methods: A literature review 
was performed to identify publications via EMBASE and MEDLINE database. Nine 
randomized controlled studies were included in this analysis based on inclusion 
criteria. The clinical results were weighted based on No. of patients to calculate 
averages for both energy devices. The total departmental cost data for electrosurgery 
group were obtained from a large US payor (PREMIER database) to apply the clini-
cal findings to calculate the cost for the Harmonic group. The total cost in laparo-
scopic cholecystectomy with two energy devices was compared to determine which 
modality is more cost effective. Results: The total case cost using an ultrasonic 
device in an inpatient laparoscopic cholecystectomy is $7701 v.s. electrosurgery is 
$8637. The use of an ultrasonic device provides a hospital savings of $936 per patient 
